Dr. Benjamin Pinsky is a clinician and professor of pathology and infectious diseases at Stanford, and the editor-in-chief of the international Journal of Clinical Virology. He directs Stanford Medicine’s Clinical Virology Laboratory, which in January launched an ambitious project to identify and track variants of the Covid-19 virus in order to provide crucial information to vaccine researchers and public health officials. Earlier this month, his lab detected the first two cases of the South African Covid-19 variant in California.
Pinsky spoke with J. from his office in Palo Alto.
Tell me about the lab’s project to find Covid variants. What are you doing?
For much of the past year, families have been separated due to risks of spreading the coronavirus. Yet as the COVID-19 vaccines continue to roll out to those.
Sutter Health and Stanford Medicine have launched a joint cancer care program that officials say will strive to expand access and state-of-the-art cancer services for patients and families in the East Bay.
®, the only FDA-cleared device platform indicated to reduce blood culture contamination
1 – today announced that unprecedented Steripath clinical study results were presented to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB).
Lucy S. Tompkins, MD, Ph.D., a professor and infectious diseases, microbiology and epidemiology expert at Stanford Health Care, presented Steripath
® Gen2 Initial Specimen Diversion Device
® (ISDD
®) phase-one study results at the PACCARB meeting in Washington, DC demonstrating unmatched reductions to blood culture contamination and false-positive central line-associated bloodstream infection (CLABSI) rates. What was even more clinically significant is that a 0.0% contamination rate and 0.0% false-positive CLABSI rate were maintained across over 11,000 blood cultures when Steripath was used throughout the course of the 10-month total trial period, continued Dr. Tompkins